Our portfolio
CEPI is working to end pandemics by supporting the research and development of a diverse portfolio of vaccine candidates.
Explore our portfolio
CEPI funds the development of vaccine candidates against our known priority pathogens and vaccine platforms to enable rapid development of vaccines against Disease X.
Our interactive portfolio provides information on each of the vaccine candidates that CEPI has invested in as well as our Centralised Lab Network, Preclinical Models and Vaccine Manufacturing Network partners.
Filter information by developer, disease, phase of development or vaccine type. You can also download a summary of our active portfolio.
Additional CEPI-funded partnerships will be added in the coming months to provide a full overview of CEPI’s investments.
Portfolio: list view
20Meds
CEPI is providing US$850,000 for the development of 20Med's bioresponsive polymeric nanoparticle technology, which could help end the need for frozen storage of mRNA vaccines. This funding will be used to advance a proof-of-concept for 20Med's nanoparticle platform, as well as for preclinical studies to assess whether the technology can deliver mRNA vaccines as effectively as the currently approved technology used for mRNA delivery, known as lipid nanoparticles.
ACM Biolabs
CEPI is providing up to US$2.87 million to ACM Biolabs for preclinical proof of concept of its mRNA delivery technology—the ACM Tunable Platform (“ATP”). ATP is a thermostable mRNA delivery vehicle that allows for mRNA storage at 2-8°C, in contrast to most existing mRNA delivery systems, which require ultra-low temperatures for storage.
The project will use Rabies as a model pathogen.
AVaxziPen
CEPI is providing up to US$1.6 million to establish proof-of-concept for aVaxziPen's vaccine-delivery technology by evaluating stability, delivery and preclinical immunogenicity of both mRNA and protein-based vaccines developed using aVaxziPen's platform.
aVaxziPen's solid-dose vaccine technology uses a pen applicator device and is designed to address access challenges associated with cold-chain storage requirements by protecting the mRNA and proteins against degradation, potentially removing the need for frozen storage for mRNA vaccines and the need for cold-chain storage altogether for protein-based vaccines.
Adaptvac
CEPI is providing up to US$12.4 Million with support from EU’s Horizon Europe programme to develop a broadly protective vaccine against several filoviruses including Ebolavirus Zaire, Sudan Ebolavirus and Marburg. AdaptVac will lead a global consortium building on AdaptVac’s innovative Virus-Like-Particle vaccine platform to create several different vaccine constructs which will be tested in preclinical studies. The most promising vaccine candidate will progress into Phase 1/2 clinical trials.
Affinivax
CEPI supported the development of a vaccine candidate based on Affinivax’s innovative Multiple Antigen Presenting System (MAPSTM) technology.
The programme aimed to establish preclinical proof of concept for a vaccine candidate designed to protect against new COVID-19 variants suitable for use in the Global South.
CEPI funding has been discontinued.
